17321-93-6

Basic information

• Product Name: 2-Amino-4-methyl-5-bromopyrimidine
• Synonyms: 5-BROMO-4-METHYL-PYRIMIDIN-2-YLAMINE;5-Bromo-4-methyl-2-aminopyrimidine;2-amino-4-methyl-5-bromopyrimidine;2-Amino-5-bromo-4-methylpyrimidine;2-PyriMidinaMine,5-broMo-4-Methyl-;2-AMino-5-broMo-4-MethylpyriMidine;2-AMino-5-broMo-4-MethylpyriMidine 97%
• CAS NO: 17321-93-6
• Molecular Formula: C₅H₆BrN₃
• Molecular Weight: 188.03
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 17321-93-6.mol
• Article Data: 11

Chemical Properties

• Melting Point: 192-194℃
• Boiling Point: 345.4 °C at 760 mmHg
• Flash Point: 162.7 °C
• Appearance: /
• Density: 1.699 g/cm³
• Vapor Pressure: 6.18E-05mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 2.47±0.10(Predicted)
• CAS DataBase Reference: 2-Amino-4-methyl-5-bromopyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4-methyl-5-bromopyrimidine(17321-93-6)
• EPA Substance Registry System: 2-Amino-4-methyl-5-bromopyrimidine(17321-93-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• WGK Germany: 3
• TSCA: N
• Hazardous Substances Data: 17321-93-6(Hazardous Substances Data)

Usage

General Description

2-Amino-4-methyl-5-bromopyrimidine is a chemical compound with the molecular formula C5H6BrN3. It is a pyrimidine derivative that contains a bromine atom, a methyl group, and an amino group. 2-Amino-4-methyl-5-bromopyrimidine is often used as a building block in organic synthesis and pharmaceutical research. It is also used in the production of various drugs and agrochemicals. The presence of the bromine atom makes 2-Amino-4-methyl-5-bromopyrimidine a versatile and valuable intermediate for the synthesis of a wide range of biologically active compounds. Its molecular structure and properties make it a useful and important chemical in the field of medicinal chemistry and drug development.

InChI:InChI=1/C5H6BrN3/c1-3-4(6)2-8-5(7)9-3/h2H,1H3,(H2,7,8,9)

Upstream product

• 108-52-1 4-Methyl-pyrimidin-2-ylamin 

Downstream Products

• 89181-77-1 4-methylpyrimidine-2,5-diamine 
• 1106312-90-6 N-[5-(2-amino-4-methyl-pyrimidin-5-yl)-2-chloro-phenyl]-benzenesulfonamide 
• 108-52-1 4-Methyl-pyrimidin-2-ylamin 
• 944401-55-2 4-methyl-5-(4,4,5,5-tetramethyl (1,3,2-dioxaborolan-2-yl))pyrimidine-2-ylamine 
• 171408-73-4 2,5-dibromo-4-methyl-pyrimidine 
• 6138-02-9 sulfanilic acid-(5-bromo-4-methyl-pyrimidin-2-ylamide) 
• 19594-45-7 5-aminomethyl-4-methyl-pyrimidin-2-ylamine 
• 17321-97-0 2-amino-4-methylpyrimidine-5-carbonitrile 
• 36082-31-2 4-acetylamino-N-(5-bromo-4-methyl-pyrimidin-2-yl)-benzenesulfonamide 
• 1823969-59-0 methyl 5-bromo-4-methylpyrimidine-2-carboxylate 
• 114969-80-1 5-bromo-4-methylpyrimidine-2-carbonitrile 
• 633328-95-7 5-bromo-2-chloro-4-methyl-pyrimidine 

Relevant articles and documents

MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF

Selective mTOR inhibitors of formulas (I)-(III), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from abnormal cell growth, functions, or behaviors mediated by an mTOR kinase and/or one or more PI3K enzyme, are provided. Such diseases and disorder include cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.